Trial intelligence / Profile preview

TEFIBEOS: Tezepelumab in progressive pulmonary fibrosis with eosinophilia

2024-510884-51-00Phase 2Suspended

Sponsor: Philipps-Universität Marburg
Start: Sep 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), chronic eosinophilic pneumonia (CEP) and 2 more comparing Tezspire arm with Placebo arm (2 arms). Primary endpoint: Change in eosinophils at 24 weeks. Started Sep 2024; status: suspended.

Drugs

tezepelumab

Conditions

idiopathic pulmonary fibrosis (IPF)progressive pulmonary fibrosis (PPF)chronic eosinophilic pneumonia (CEP)hypersensitivity pneumonitis (HP)connective tissue disease-associated interstitial lung disease (CTD-ILD)

Beyond the preview

Go deeper on 2024-510884-51-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-510884-51-00.